The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi‐allelic gene deletion

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Pathology

• Publication date

  2006-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/path.1929PMID 16402365
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Insights from genomic microarrays into structural chromosome rearrangements

  2005cited by this paper
• Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.

  2005cited by this paper
• Cancer Statistics, 2005

  2005cited by this paper
• Evaluation of genetic patterns in different tumor areas of intermediate‐grade prostatic adenocarcinomas by high‐resolution genomic array analysis

  2004cited by this paper
• Loss of a small region around the PTEN locus is a major chromosome 10 alteration in prostate cancer xenografts and cell lines

  2004cited by this paper
• Pten Dose Dictates Cancer Progression in the Prostate

  2003cited by this paper
• Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.

  2003cited by this paper
• DNA microarrays for comparative genomic hybridization based on DOP‐PCR amplification of BAC and PAC clones

  2003cited by this paper
• Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer.

  2003cited by this paper
• Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases.

  2003cited by this paper
• Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas.

  2002cited by this paper
• Prognostic factors in localised prostate cancer with emphasis on the application of molecular techniques.

  2002cited by this paper
• Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice.

  2002cited by this paper
• Molecular Cloning: A Laboratory Manual

  2001cited by this paper
• Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse

  2001cited by this paper
• Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression

  2001cited by this paper
• Mutations of PTEN/MMAC1 in primary prostate cancers from Chinese patients.

  2001cited by this paper
• Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.

  1999cited by this paper
• New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway.

  1999cited by this paper
• Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity.

  1999cited by this paper
• Identification of the critical region of 12p over-representation in testicular germ cell tumors of adolescents and adults

  1998cited by this paper
• Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.

  1998cited by this paper
• Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN.

  1998cited by this paper
• Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.

  1998cited by this paper
• Analysis of PTEN and the 10q23 region in primary prostate carcinomas

  1998cited by this paper
• Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas.

  1998cited by this paper
• Frequent inactivation of PTEN in prostate cancer cell lines and xenografts.

  1998cited by this paper
• PTEN/MMAC1/TEP1 involvement in primary prostate cancers

  1998cited by this paper
• PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate

  1998cited by this paper
• Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.

  1997cited by this paper
• Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome

  1997cited by this paper
• PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer

  1997cited by this paper
• Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

  1997cited by this paper
• Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections.

  1991cited by this paper

• Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial.

  2025cites this paper
• The prognostic value of PTEN expression in localized prostate cancer

  2025cites this paper
• Genitourinary Pathology (Including Adrenal Gland)

  2020cites this paper
• V-ATPase-associated prorenin receptor is upregulated in prostate cancer after PTEN loss

  2019cites this paper
• Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.

  2019cites this paper
• Precise Immunodetection of PTEN Protein in Human Neoplasia.

  2019influential citation
• Prostate-specific loss of UXT promotes cancer progression

  2019cites this paper
• Loss of PTEN Accelerates NKX3.1 Degradation to Promote Prostate Cancer Progression.

  2019cites this paper
• Identifying small molecule probes of ENTPD5 through high throughput screening

  2018cites this paper
• Distinct subtypes of genomic PTEN deletion size influence the landscape of aneuploidy and outcome in prostate cancer

  2018cites this paper
• The validity of Immunohistochemical Expression of PTEN protein in detecting PTEN gene deletion in Prostate cancer

  2018cites this paper
• PI3K/Akt/mTOR/PTEN and ERK/MAPK Pathways

  2018cites this paper
• The molecular mechanism of ovarian granulosa cell tumors

  2018cites this paper
• Molecular Biomarkers in the Clinical Management of Prostate Cancer.

  2018cites this paper
• Clinical implications of PTEN loss in prostate cancer

  2018cites this paper
• Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA

  2018cites this paper
• New and Emerging Diagnostic and Prognostic Immunohistochemical Biomarkers in Prostate Pathology

  2017cites this paper
• Identification of biomarkers for the management of human prostate cancer

  2017cites this paper
• Development of transcriptional amplification systems to target and characterize cancer cells based on gene expression altered during prostate cancer development and treatment

  2017cites this paper
• PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort

  2017cites this paper
• Molecular Pathology of Prostate Cancer

  2017cites this paper
• Clinical significance of PSMA, TERT and PDEF in malignant tumors of the prostate.

  2017cites this paper
• Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data

  2017cites this paper
• Prostate cancer, PI3K, PTEN and prognosis.

  2017cites this paper
• Non-androgen Signaling Pathways in Castration-Resistant Prostate Cancer

  2016cites this paper
• Targeting Chemotherapy Resistance in Glioblastoma Through Modulation of ABC Transporters

  2016cites this paper
• PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer.

  2016cites this paper
• Advances in prostate cancer research models: From transgenic mice to tumor xenografting models

  2016cites this paper
• In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading

  2016cites this paper
• Award Number: W81XWH-13-1-0271 TITLE: Molecular Profiling of Intraductal Carcinoma of the Prostate PRINCIPAL INVESTIGATOR:

  2016cites this paper
• Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy

  2016cites this paper
• Analytic Validation of a Clinical-Grade PTEN Immunohistochemistry Assay in Prostate Cancer by Comparison to PTEN FISH

  2016cites this paper
• PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate

  2015cites this paper
• PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas

  2015cites this paper
• Genitourinary System Tumors

  2015cites this paper
• Original Article PTEN genomic deletion defines favorable prognostic biomarkers in localized prostate cancer: a systematic review and meta-analysis

  2015cites this paper
• PTEN genomic deletion defines favorable prognostic biomarkers in localized prostate cancer: a systematic review and meta-analysis.

  2015cites this paper
• Exploring mechanisms of prostate tumourigenesis in mouse models

  2015cites this paper
• PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients

  2015cites this paper
• Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1‐mediated survivin function and delaying DNA repair in prostate cancer models

  2014cites this paper
• PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer

  2014cites this paper
• NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype

  2014cites this paper
• ROLE OF TALIN1 PHOSPHORYLATION IN BETA1 INTEGRIN ACTIVATION AND PROSTATE CANCER METASTASIS

  2014cites this paper
• Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer

  2014cites this paper
• Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic.

  2014cites this paper
• Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (review).

  2014cites this paper
• Nucleic acid-based tissue biomarkers of urologic malignancies

  2014cites this paper
• Salvage Treatment for Recurrent Prostate Cancer Following Brachytherapy: For Whom, When and Which?

  2013cites this paper
• The PI3 kinase signaling pathway in prostate cancer.

  2013cites this paper
• Gata3 antagonizes cancer progression in Pten-deficient prostates.

  2013cites this paper
• Disruption of Prostate Epithelial Differentiation Pathways and Prostate Cancer Development

  2013cites this paper
• PTEN in Prostate Cancer

  2013cites this paper
• A Three-Marker FISH Panel Detects More Genetic Aberrations of AR, PTEN and TMPRSS2/ERG in Castration-Resistant or Metastatic Prostate Cancers than in Primary Prostate Tumors

  2013cites this paper
• Lineage relationship of Gleason patterns in Gleason score 7 prostate cancer.

  2013cites this paper
• Chemotherapy and Novel Systemic Approaches in the Treatment of Metastatic Castration Resistant Prostate Cancer

  2013cites this paper
• Apoptosis and Autophagy

  2013cites this paper
• The Role of MYC Rearrangements and Relative Copy Number Gain in Prostate Cancer

  2013cites this paper
• Guidelines on Prostate Cancer

  2013cites this paper
• Loss of pSer2448‐mTOR expression is linked to adverse prognosis and tumor progression in ERG‐fusion‐positive cancers

  2013cites this paper
• Notch signaling pathway as a mediator for early detection and modulation of aggressiveness of prostate cancer

  2013cites this paper
• Altered PTEN function caused by deletion or gene disruption is associated with poor prognosis in rectal but not in colon cancer.

  2013cites this paper
• PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade

  2013cites this paper
• Recruitment of Normal Stem Cells to an Oncogenic Phenotype by Noncontiguous Carcinogen-Transformed Epithelia Depends on the Transforming Carcinogen

  2013cites this paper
• Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer

  2012cites this paper
• Investigation of Novel Progression-related Methylation Events and HOXD Genes in Prostate Cancer

  2012cites this paper
• Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.

  2012cites this paper
• Cytoplasmic PTEN Protein Loss Distinguishes Intraductal Carcinoma of the Prostate from High Grade Prostatic Intraepithelial Neoplasia

  2012cites this paper
• Germline BRCA mutation does not prevent response to taxane‐based therapy for the treatment of castration‐resistant prostate cancer

  2012cites this paper
• PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity

  2012influential citation
• PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications

  2012influential citation
• Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer

  2012cites this paper
• Arsenic-Transformed Malignant Prostate Epithelia Can Convert Noncontiguous Normal Stem Cells into an Oncogenic Phenotype

  2012cites this paper
• Estudi dels gens FGFR3, EGFR, PTEN, CXCR4 i del gen de fusió TMPRSS2-ERG en càncer de pròstata

  2012cites this paper
• Global Characterization of Protein-Altering Mutations in Prostate Cancer

  2011cites this paper
• The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.

  2011cites this paper
• PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients

  2011cites this paper
• Animal models relevant to human prostate carcinogenesis underlining the critical implication of prostatic stem/progenitor cells.

  2011cites this paper
• SIGLEC12, a Human-specific Segregating (Pseudo)gene, Encodes a Signaling Molecule Expressed in Prostate Carcinomas*

  2011cites this paper
• Lotan and De Marzo et al 1 PTEN Protein Loss by Immunostaining : Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients

  2011influential citation
• Germ-line sequence variants of PTEN do not have an important role in hereditary and non-hereditary prostate cancer susceptibility

  2011cites this paper
• Signalling Pathways and Gene Expression Profiles in Prostate Cancer

  2011cites this paper
• Androgen action during prostate carcinogenesis.

  2011cites this paper
• Advanced Models for Target Validation & Drug Discovery in Prostate Cancer

  2011cites this paper
• Prostate cancer as a model system for genetic diversity in tumors.

  2011cites this paper
• Topographical analysis of telomere length and correlation with genomic instability in whole mount prostatectomies

  2011cites this paper
• Prognostic Implications of Important Genetic Alterations in Prostate Cancer

  2011cites this paper
• The tumorigenicity-promoting activity of C-FABP in prostate cancer cells depends on its fatty acid-binding ability

  2011cites this paper
• Imaging , Diagnosis , Prognosis PTEN Protein Loss by Immunostaining : Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients

  2011cites this paper
• PTEN‐mediated G1 cell‐cycle arrest in LNCaP prostate cancer cells is associated with altered expression of cell‐cycle regulators

  2010cites this paper
• Guía clínica sobre el cáncer de próstata

  2010cites this paper
• PATHOLOGY OF THREE TRANSGENIC MOUSE LINES WITH UNIQUE PTEN MUTANT ALLELES

  2010cites this paper
• Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer

  2010cites this paper
• E17K substitution in AKT1 in prostate cancer

  2010cites this paper
• Tumors of the male genital organs

  2010cites this paper
• Molecular genetics of prostate cancer: new prospects for old challenges.

  2010cites this paper
• Рак предстательной железы

  2010cites this paper
• Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.

  2009cites this paper
• Unraveling of the major genetic defects in prostate cancer

  2009cites this paper
• Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer

  2009cites this paper
• Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma

  2009cites this paper